More recently, a synthetic consensus sequence approach to provide MHC class II help was used to develop a FAP DNA vaccine, which was shown to synergize with other tumor antigen-specific DNA vaccines to enhance CD8+ and CD4+ antitumor immunity [228]. This evidence concerns the gene CD8A and neoplasm.